Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 15/20 | 0.50 |
| ▸ | EDNRA | P25101 | 15/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.50 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067633 | 1.00 | EDNRB (0.50) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL570417 | 1.00 | EDNRB (0.50) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL28079200 | 0.98 | EDNRB (0.49) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL28079191 | 0.98 | EDNRB (0.49) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL28227186 | 0.98 | EDNRB (0.49) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL28079222 | 0.98 | EDNRB (0.49) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Valine SCHEMBL17965930 | 0.87 | SLC7A5 (0.44) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL4436073 | 0.87 | EDNRB (0.40) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL4440829 | 0.87 | EDNRB (0.40) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL14886539 | 0.87 | EDNRB (0.46) | EDNRBEDNRANR1I2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110437063-B | Preparation method of ambrisentan key intermediate | 常州恒邦药业有限公司 | 2022-04-29 | — | — | CN | claimed |
| CN-111099993-B | Preparation method of (S) -2-hydroxy-3-methoxy-3, 3-diphenyl propionic acid | 常州恒邦药业有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-108250151-B | Preparation method of ambrisentan | 济南周行医药科技有限公司 | 2021-03-16 | — | — | CN | claimed |
| CN-111099993-A | Preparation method of (S) -2-hydroxy-3-methoxy-3, 3-diphenyl propionic acid | 常州恒邦药业有限公司 | 2020-05-05 | — | — | CN | claimed |
| CN-110437063-A | The preparation method of ambrisentan key intermediate | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD | 2019-11-12 | — | — | CN | claimed |
| CN-103396370-B | A kind of purification process of ambrisentan | 浙江华海药业股份有限公司 | 2018-11-16 | — | — | CN | claimed |
| CN-108250151-A | A kind of preparation method of ambrisentan | 济南周行医药科技有限公司 | 2018-07-06 | — | — | CN | claimed |
| CN-104098462-B | The method for splitting of the diphenyl-propionic acid racemoid of 2 hydroxyl, 3 methoxyl group 3,3 | 江苏豪森药业集团有限公司 | 2017-11-17 | — | — | CN | claimed |
| CN-103086877-B | A kind of method for splitting of 2 hydracrylic acid class racemoid | 浙江华海药业股份有限公司 | 2017-08-25 | — | — | CN | claimed |
| US-9533960-B2 | Preparation process of carboxylic acid derivatives and intermediates thereof | KERN PHARMA, S.L. (ES) | 2017-01-03 | — | — | US | claimed |
| US-20130184490-A1 | PROCESS TO PREPARE S-2-HYDROXY-3-METHOXY-3,3-DIPHENYL PROPIONIC ACID | NATCO PHARMA LIMITED (IN) | 2013-07-18 | — | — | US | claimed |
| US-8404840-B2 | Process for the preparation of endothelin receptor antagonists | MSN LABORATORIES LIMITED (IL) | 2013-03-26 | — | — | US | claimed |
| US-20130060031-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE AMBRISENTAN | NATCO PHARMA LIMITED (IN) | 2013-03-07 | — | — | US | claimed |
| US-20120184573-A1 | PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2012-07-19 | — | — | US | claimed |
| EP-2451786-A2 | IMPROVED PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF | Cadila Healthcare Limited (IN) | 2012-05-16 | — | — | EP | claimed |
| WO-2012017441-A1 | IMPROVED PROCESS TO PREPARE S-2-HYDROXY-3-METHOXY-3,3-DIPHENYL PROPIONIC ACID | NATCO PHARMA LIMITED (IN) | 2012-02-09 | — | — | WO | claimed |
| US-20110263854-A1 | Improved Process For The Preparation Of Endothelin Receptor Antagonists | MSN LABORATORIES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| EP-2350024-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS | MSN Laboratories Limited (IN) | 2011-08-03 | — | — | EP | claimed |
| WO-2010091877-A2 | PROCESS FOR PRODUCING AMBRISENTAN | RATIOPHARM GMBH (DE) | 2010-08-19 | — | — | WO | claimed |
| WO-2010070658-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS | MSN LABORATORIES LIMITED (IN) | 2010-06-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060031-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE AMBRISENTAN | AGTR2, PDE7A, ACVR1B | EDNRB 4/4885EDNRA 10/4885NR1I2 3650/4885 |
| US-20130184490-A1 | PROCESS TO PREPARE S-2-HYDROXY-3-METHOXY-3,3-DIPHENYL PROPIONIC ACID | PAH, TGFB2, TGFBR2 | EDNRB 29/4885EDNRA 26/4885NR1I2 2862/4885 |
| US-20110263854-A1 | Improved Process For The Preparation Of Endothelin Receptor Antagonists | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885NR1I2 2109/4885 |
| US-20120184573-A1 | PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF | ACVR1, ACVR1B, CYP11B1 | EDNRB 7/4885EDNRA 27/4885NR1I2 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.